Subgroup | Statistic | ADA 40 mg SC q2w, n=162 | TCZ 8 mg/kg IV q4w, n=162 |
---|---|---|---|
Lp(a) (mg/dL) | |||
Baseline | |||
n | 162 | 162 | |
Mean (SD) | 25.5 (30.2) | 22.4 (25.5) | |
min, max | 4.0, 194.0 | 4.0, 131.0 | |
Change from baseline to week 8 | |||
n | 157 | 156 | |
Mean (SD) | –1.1 (15.1) | –7.6 (12.0) | |
min, max | –102.5, 86.4 | –60, 21.9 | |
Difference in adjusted means (95% CI)† | –7.12 (–9.9 to –4.4) | ||
p Value‡ | <0.0001 |
*Includes only patients with both baseline and week 8 values.
†Difference and 95% CI based on adjusted least square means (TCZ-ADA).
‡ANCOVA model was adjusted for baseline Lp(a). p Values were unadjusted for multiple testing; therefore, no statistical significance can be claimed.
ADA, adalimumab; ANCOVA, analysis of covariance; IV, intravenous; Lp(a), lipoprotein (a); q2w, every 2 weeks; q4w, every 4 weeks; SC, subcutaneous; TCZ, tocilizumab.